Dr Reddys Laboratories Ltd (500124)
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, effective July 22, 2026
- Dr. Sridevi brings over 20 years of biopharmaceutical leadership experience
- Former CEO of Shilpa Biologics; prior roles at Syngene International and Intas Biopharma
- Previously led Product Development and Quality Control at Dr Reddy's
- Holds a PhD from NCBS (TIFR) and postdoc from Stanford
- Deloitte Haskins & Sells LLP appointed as Independent Registered Public Accounting Firm for auditing and SEC filings
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 500124 — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add 500124 to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Dr Reddys Laboratories Ltd
Important.
The summary above is generated automatically from Dr Reddys Laboratories Ltd's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.